These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 9923042)

  • 1. Iloprost as cyclic five-day infusions in the treatment of scleroderma. An open pilot study in 20 patients treated for one year.
    Biasi D; Carletto A; Caramaschi P; Zeminian S; Pacor ML; Corrocher R; Bambara LM
    Rev Rhum Engl Ed; 1998 Dec; 65(12):745-50. PubMed ID: 9923042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient treatment of severe peripheral ischemia with intravenous intermittent low-dose iloprost. An open pilot study.
    Banyai S; Jenelten R; Wagner S; Allmann J; Banyai M; Koppensteiner R
    Int Angiol; 2002 Mar; 21(1):36-43. PubMed ID: 11941272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term evaluation of lung function in patients affected by scleroderma treated with cyclic iloprost infusions.
    Caramaschi P; Biasi D; Ferrari M; Volpe A; Martinelli N; Carletto A; Dal Forno P; Bambara LM
    Rheumatol Int; 2005 May; 25(4):250-4. PubMed ID: 14963694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
    Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE
    Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
    Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
    Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
    Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
    Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
    Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
    Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases.
    Zulian F; Corona F; Gerloni V; Falcini F; Buoncompagni A; Scarazatti M; Martini G; Zacchello F
    Rheumatology (Oxford); 2004 Feb; 43(2):229-33. PubMed ID: 12923288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Period of remission after treatment with UVA-1 in sclerodermic skin diseases.
    Kroft EB; van de Kerkhof PC; Gerritsen MJ; de Jong EM
    J Eur Acad Dermatol Venereol; 2008 Jul; 22(7):839-44. PubMed ID: 18452527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Madecassol treatment of systemic and localized scleroderma].
    Guseva NG; Starovoĭtova MN; Mach ES
    Ter Arkh; 1998; 70(5):58-61. PubMed ID: 9644746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.
    Várai G; Earle L; Jimenez SA; Steiner RM; Varga J
    J Rheumatol; 1998 Jul; 25(7):1325-9. PubMed ID: 9676764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
    Bérezné A; Ranque B; Valeyre D; Brauner M; Allanore Y; Launay D; Le Guern V; Kahn JE; Couderc LJ; Constans J; Cohen P; Mahr A; Pagnoux C; Hachulla E; Kahan A; Cabane J; Guillevin L; Mouthon L
    J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma.
    Clegg DO; Reading JC; Mayes MD; Seibold JR; Harris C; Wigley FM; Ward JR; Pisko EJ; Weisman MH; Lee P
    J Rheumatol; 1994 Jan; 21(1):105-10. PubMed ID: 8151563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis.
    Apras S; Ertenli I; Ozbalkan Z; Kiraz S; Ozturk MA; Haznedaroglu IC; Cobankara V; Pay S; Calguneri M
    Arthritis Rheum; 2003 Aug; 48(8):2256-61. PubMed ID: 12905480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial.
    Clements PJ; Wong WK; Hurwitz EL; Furst DE; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Seibold JR
    Arthritis Rheum; 2001 Mar; 44(3):653-61. PubMed ID: 11263780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
    DeMarco PJ; Weisman MH; Seibold JR; Furst DE; Wong WK; Hurwitz EL; Mayes M; White B; Wigley F; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
    Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.
    Gerloni V; Pontikaki I; Gattinara M; Desiati F; Lupi E; Lurati A; Salmaso A; Fantini F
    Arthritis Rheum; 2005 Feb; 52(2):548-53. PubMed ID: 15693004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of nebulised iloprost on pulmonary function and gas exchange in severe pulmonary hypertension.
    Reichenberger F; Mainwood A; Doughty N; Fineberg A; Morrell NW; Pepke-Zaba J
    Respir Med; 2007 Feb; 101(2):217-22. PubMed ID: 16831539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.